Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00993824

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Sponsor: Daiichi Sankyo

Conditions Type 2 Diabetes

Interventions colesevelam HCl placebo

Updated 9 times since 2017 Last updated: Nov 25, 2015 Started: Sep 30, 2009 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00993824, this PHASE2/PHASE3 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Daiichi Sankyo, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2023 — Mar 2024 [monthly]

Completed PHASE2_PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2_PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Sep 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo
HealthPartners Institute
International Diabetes Center at Park Nicollet

Data source: HealthPartners Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States